PET imaging study reveals how ketamine relieves treatment-resistant depression
Medical Xpress
March 6, 2026
Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies. Although ketamine has emerged as a rapid-acting antidepressant for individuals with TRD, its underlying biological mechanism in the human brain has remained poorly understood, limiting efforts to optimize and personalize treatment.
Verticals
healthmedical
Originally published on Medical Xpress on 3/6/2026